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Abstract (word count 128) 
Several prescription and non-prescription drugs are liable for abuse. However, oral 
hypoglycemic agents are among the most benign and low risk drugs in terms of abuse 
liability.  This Commentary intends to raise awareness regarding the abuse of a 
particular type of oral hypoglycemic agent, namely sulfonylurea drugs, used to 
experience mental altering effects for its euphoric “hypoglycemic rush”.  Information is 
available on discussion fora online where people exchange their experiences.  
Moreover, several case reports have been published and described the liability for 
abuse of sulfonylurea drugs. This article intends to shed the light on this phenomenon in 
light of available literature, attempting to explain the possible scientific basis for it. In 
addition, it highlights the need for health professional awareness and vigilance for this 
form of drug diversion.  
Impact on practice: 
 Raising awareness of clinicians about the underestimated, under-researched
issue of hypoglycemic drug abuse.
 Explaining the potential abuse of hypoglycemic rush in light of published scientific
literature.
 Making recommendations to legislative authorities in some countries to limit
access to sulfonylurea drugs to be available strictly on prescription.
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The aim of writing this Commentary is to shed the light on a briefly reported and dated 27 
form of intentional drug intoxication known as “factitious hypoglycemia” [1,2] which 28 
appears to be re-emerging in recent times [1,3]. We refer to the phenomenon of abuse of 29 
a particular type of oral hypoglycemic agents, namely sulfonylurea drugs, used to 30 
experience mental altering effects for its euphoric “hypoglycemic rush” [1].  We utilize the 31 
definition of abuse whereby intentional use of pharmaceutical medicines is for non-32 
medical purposes, rather than accidental overdose [4]. Anecdotal web discussions  [5] 33 
and case reports of Marchetti et al 1988 and Svirski and Edoute 1996 [6,7] center on the 34 
use of sulfonylurea drugs to experience a “near coma” state, which users describe as 35 
“joyful” or “euphoric”. [3,5] Such mind altering effects are caused by the deliberate 36 
inducement of hypoglycemia or referred to as “factitious hypoglycemia” [6,7]. A narrative 37 
review was conducted and designed to present a broad perspective on abuse or misuse 38 
of oral hypoglycemic agents, and describe its history and development in terms of how 39 
common it is and its public health implications. A structured literature search was 40 
conducted based on the question; what is currently known about liability of sulfonylureas 41 
to abuse? Search terms include sulfonylureas, oral hypoglycemic agents, glibenclamide, 42 
glyburide, different brand names, and “euphoria”,“high”,“hypoglycemic rush”. There was 43 
no restriction on date range, and all types of articles, including opinion pieces were 44 
included. 45 
In general, oral hypoglycemic agents are among the most benign and low risk 46 
drugs in terms of potential abuse liability. However, on conducting this rapid review of 47 
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web discussions and extant literature, we wish to draw the readership’s attention to this 48 
unique form of intoxicating and non-medical intentional use of sulfonylurea drugs. We 49 
know that those interested in alternative ways of getting “high” are constantly in search 50 
for new alternatives that are available, cheap and legal and replace those drugs which 51 
are harder to obtain, more expensive illicit drugs. [8,9] For example, more unusual forms 52 
of pharmaceutical medicinal diversion include those with little or no mental altering effects 53 
such as bisoprolol, table salt or menthol vapor rubs [8-10]. Hence, we report here on the 54 
case of abuse of sulfonylureas, whereby the reported intoxication effect is caused by 55 
adrenaline release [11,12]. Adrenaline is responsible for the feeling of “rush” and 56 
contribution to dependence type behavior [11,12].  57 
Normally, the brain utilizes glucose as sole energy source, which makes it 58 
particularly sensitive to any decrease in blood glucose level. When blood glucose levels 59 
drop too low, the body tries to increase the amount of glucose available in the bloodstream 60 
by releasing hormones such as glucagon and epinephrine (also called adrenaline) that 61 
stimulate the release of glycogen from the liver [13]. Symptoms of hypoglycemia are 62 
caused by a combination of adrenaline release and low glucose in the brain. Adrenaline 63 
can cause anxiety, shaking, sweating, tachycardia, and emotional reactivity such as 64 
irritability, anger and tears, “brain fog,” fatigue and insomnia [14]. These symptoms are 65 
often called the “warning signs” of hypoglycemia [13].  Lack of glucose to the brain can 66 
cause  difficulties in concentration, blurred vision, slurred speech, lack of coordination, 67 
headaches, dizziness, and drowsiness. Hypoglycemia can also cause changes in 68 
emotions and mood. Feelings of nervousness and irritability, becoming argumentative, 69 
showing aggression, and crying are common, although some people experience euphoria 70 
4 
 
and giddiness [14]. “Factitious hypoglycemia” occurs secondary to the surreptitious use 71 
of insulin or insulin secretagogues (sulfonylureas, meglitinides). It can be differentiated 72 
from fasting hypoglycemia caused by hyperinsulinaemia or injection of insulin, by an 73 
elevated (> 1.0) molar ratio of insulin to C-peptide [15]. When sulfonylurea preparations 74 
are consumed, the only way of distinguishing factitious hypoglycemia from insulinoma is 75 
by determining the drug in serum and urine [14]. 76 
 77 
We conducted a rapid assessment of web discussions and review of extant literature 78 
which describe this unique form of pharmaceutical medicinal abuse whereby consumers 79 
deliberately ingest large doses of glibenclamide (also known as Glyburide) of up to 80 
50mg at once to cause hypoglycemia and induce associated euphoric effects [6,7,16]. 81 
We note that the maximum daily dose ranges between 12 mg (micronized form) to 20 82 
mg (standard glibenclamide) [17]. Several cases of deliberate inducement of 83 
hypoglycemia [6,7,16] described varied reasons for such excessive consumption, either 84 
to experience drug induced euphoria [16], or in seeking attention caused by Munchasen 85 
syndrome [18]. Of note are that case reporting occurs in the majority in medical 86 
personnel, diabetics or members of their family [14,16].  There are several factors 87 
contributing to such increased risk of drug abuse among medical personnel, such as 88 
emotional stress at work and easy access to drugs. [19] In addition, healthcare 89 
professionals’ over-confidence may lead them to believe that their medical competency 90 
will prevent problems relating to acute intoxication and misuse of such drugs.. [19] A 91 
survey of 60 adolescents (12-20 years old) with Type-1 diabetes mellitus revealed a 92 
36.7% prevalence of substance (alcohol, tobacco, illicit drugs) use and 19% reported 93 
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insulin misuse. [20] In this study, self-harm intent was reported by one-third of insulin 94 
misusers. Substance use and insulin misuse were not related to glycemic control or 95 
diabetes self-management behaviors.[20] 96 
 97 
Despite the low case reporting, web discussions register an interest in “factitious 98 
hypoglycemia” as evidence by the following comments; “I like the feeling. until it starts 99 
getting crazy intense, then it's like I guess I should do something about this”, “mild 100 
hypoglycemia feels good to me. I feel like I have been day drinking”, “I know alot of 101 
people describe having a hypo like being drunk, but at least you know why you're 102 
drunk.” “I bet if there was a way to safely get your levels down to a hypo level and keep 103 
them there people would use it as a drug.” [5]. 104 
Hence we wish to draw attention to this unique form of pharmaceutical medicinal 105 
abuse for intoxication purposes, and the need for health professional awareness of and 106 
vigilance for this form of diversion and patient misuse of their drugs. In addition medical 107 
and pharmacy practitioners are advised to be aware of  symptomatologies of “factitious 108 
hypoglycemia” and the need for pharmacovigilance  109 
 110 
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